SCHEINER, BERNHARD
 Distribuzione geografica
Continente #
AS - Asia 38
EU - Europa 33
NA - Nord America 15
Totale 86
Nazione #
SG - Singapore 24
US - Stati Uniti d'America 15
IT - Italia 14
HK - Hong Kong 8
IE - Irlanda 6
IN - India 4
CH - Svizzera 3
AT - Austria 2
FI - Finlandia 2
NL - Olanda 2
RU - Federazione Russa 2
CN - Cina 1
DE - Germania 1
GB - Regno Unito 1
KR - Corea 1
Totale 86
Città #
Singapore 18
Hong Kong 8
Dublin 6
Boardman 3
Zurich 3
Amsterdam 2
Deiva Marina 2
Helsinki 2
New Delhi 2
Ryazan 2
Santa Clara 2
Vienna 2
Islington 1
Mezzomerico 1
Milan 1
Naples 1
Palermo 1
Seoul 1
Totale 58
Nome #
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 11
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 10
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 10
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 9
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 8
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 7
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 7
Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis 6
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 6
Tumor-infiltrating Neutrophils: Gatekeepers in Liver Cancer Immune Control 6
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 6
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 5
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 5
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 5
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 2
Totale 103
Categoria #
all - tutte 2.307
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.307


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202459 16 1 6 1 8 0 8 4 0 1 0 14
2024/202544 8 0 30 2 4 0 0 0 0 0 0 0
Totale 103